Diffuse large b-cell lymphoma in advanced stages can be treated with immunochemotherapy and targeted therapy. Diffuse large b-cell lymphoma is a medium to highly malignant tumor, which is prone to recurrent dissemination as far as its biological characteristics are concerned, and the cancer cells will infiltrate and invade in the diaphragm, lymph node tissues, and extra-nodal organs. The advanced stage of diffuse large b-cell lymphoma is more sensitive to treatment compared with the advanced stage of other solid tumors, so even if the patient is in the advanced stage, he or she will get a good treatment effect through immunochemotherapy and targeted therapy. The drugs include cyclophosphamide, doxorubicin, vincristine, rituximab, etc., which can prolong the survival of patients and improve their quality of life. If patients are diagnosed with diffuse large b-cell lymphoma, it is recommended that they undergo standardized treatment under the guidance of a physician as early as possible in order to reduce the adverse effects of the disease.